Three small-molecule CDK4/6 inhibitors (palbociclib, abemabiclib and ribociclib) are clinically approved for the treatment of metastatic ER+/HER2− breast cancer, and their use in the treatment of other cancers is an area of active investigation [1–9]. Here, CDK4 is linked to cancer.